Objective To observe the action and correlation of p16 and estrogen receptor (ER) in papillary thyroid cancer (PTC).
Methods Using immunohistochemical method, the p16 and ER in 50 cases of PTC were detected.
Results The expression of p16 and ER was associated with the cellular differentiation, the lymphatic metastasis and prognosis in PTC.
Conclusion It is helpful to detect the p16 protein and ER for analyzing the cellular differentiation degree and prognosis in PTC.
Citation：
LIU Jun,WANG Zhanming,WANG Lei.. THE EXPRESSION AND CORRELATION OF p16 PROTEIN AND ESTROGEN RECEPTOR IN PAPILLARY THYROID CANCER. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2000, 7(5): 295-296. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
Paloyan E, Hofmann C, Richard A, et al. Gastriation induces a marked reduction in the incidence of thyroid cancers 〔Ｊ〕. Surgery, 1982; 92(5)∶839.
|
| 2. |
Miki H, Oshimo K, Inoue H, et al. Sex hormone receptor in human thyroid tissues 〔Ｊ〕. Cancer, 1990; 66(8)∶1759.
|
| 3. |
刘军， 王占民， 张太保. 甲状腺乳头状癌性激素受体的检测 〔Ｊ〕. 山东医科大学学报， 1999； 37(4)∶331.
|
| 4. |
Yane K, Konishi N, Kitahori Y, et al. Lack of p16/CDKN2 alterations in thyroid carcinomas 〔Ｊ〕. Cancer Lett, 1996; 101(1)∶85.
|
| 5. |
Reed JA, Loganzo FJr, Shea CR, et al. Loss expression of the p16/cyclindependent kinase inhibitor 2 tumor suppressor gene inmelanocytic lesions correlates with invasive stage of tumor progression 〔Ｊ〕. Cancer Res, 1995; 55(10)∶2713.
|
| 6. |
郭山春， 廖松林， 丁华野等. 乳腺癌p16基因表达与增殖细胞核抗原指数的相关性 〔Ｊ〕. 中华医学杂志， 1997； 77(7)∶529.
|
| 7. |
Wadih A, Ryo N, Frank B, et al. Replacement of the p16/CDKN2 gene suppresses human gliioma cell growth 〔Ｊ〕. Cancer Res, 1995; 55(3)∶1351.
|
| 8. |
VanHoeven, MenendezBotet, Elliot W, et al. Estrogen and progesterone receptor content in human thyroid diseases 〔Ｊ〕. Am J Clin Pathol, 1993; 99(2)∶175.
|
- 1. Paloyan E, Hofmann C, Richard A, et al. Gastriation induces a marked reduction in the incidence of thyroid cancers 〔Ｊ〕. Surgery, 1982; 92(5)∶839.
- 2. Miki H, Oshimo K, Inoue H, et al. Sex hormone receptor in human thyroid tissues 〔Ｊ〕. Cancer, 1990; 66(8)∶1759.
- 3. 刘军， 王占民， 张太保. 甲状腺乳头状癌性激素受体的检测 〔Ｊ〕. 山东医科大学学报， 1999； 37(4)∶331.
- 4. Yane K, Konishi N, Kitahori Y, et al. Lack of p16/CDKN2 alterations in thyroid carcinomas 〔Ｊ〕. Cancer Lett, 1996; 101(1)∶85.
- 5. Reed JA, Loganzo FJr, Shea CR, et al. Loss expression of the p16/cyclindependent kinase inhibitor 2 tumor suppressor gene inmelanocytic lesions correlates with invasive stage of tumor progression 〔Ｊ〕. Cancer Res, 1995; 55(10)∶2713.
- 6. 郭山春， 廖松林， 丁华野等. 乳腺癌p16基因表达与增殖细胞核抗原指数的相关性 〔Ｊ〕. 中华医学杂志， 1997； 77(7)∶529.
- 7. Wadih A, Ryo N, Frank B, et al. Replacement of the p16/CDKN2 gene suppresses human gliioma cell growth 〔Ｊ〕. Cancer Res, 1995; 55(3)∶1351.
- 8. VanHoeven, MenendezBotet, Elliot W, et al. Estrogen and progesterone receptor content in human thyroid diseases 〔Ｊ〕. Am J Clin Pathol, 1993; 99(2)∶175.
